"When menopause comes, should I have hormone therapy, and if so, when is it best to start?" It is one of the questions I hear most often in the clinic. To be honest, there is no single right answer that applies the same to everyone. Because the rhythm of hormones, accompanying diseases, lifestyle, and genetic constitution differ from person to person. Recently, a current has emerged of looking at blood tests, symptom records, and wearable data together to gauge more three-dimensionally "whether now is the appropriate time for this person." In this article, let me organize why the start timing of hormone therapy matters, and how data helps that decision and also up to where it can help.
Why the start timing matters in hormone therapy
In hormone therapy, the start timing above all affects the result. The core of the evidence accumulated so far is that even using the same drug, the balance of benefit and risk differs according to how long after menopause it was started. This concept is commonly called the timing hypothesis.
The North American Menopause Society (NAMS), in its 2022 hormone therapy position statement, organized that when a healthy woman is under 60 or within 10 years of menopause, a tendency is reported for benefit to exceed risk in terms of relieving vasomotor symptoms (hot flashes, sweating) and preventing bone loss. Conversely, it held that when first starting past age 60 or when much time has passed since menopause, the weight on the risk side may grow larger.
This "relatively early period" is also called the window of opportunity or the critical window. However, this is not a uniform deadline but a concept whose interpretation differs according to one's health status. If you are curious about the changes around menopause, reading the mechanism of menopausal symptoms together helps.
Studies that back the timing hypothesis
The timing hypothesis has been examined not as a mere clinical impression but with designed studies. Representatively, the ELITE study (reported in 2016) is a randomized clinical trial that compared the influence of estradiol by dividing women who were under 6 years post-menopause and those 10 or more years post-menopause.
In this study, in the group that started relatively early after menopause, the progression of carotid intima-media thickness appeared slower, whereas the same pattern was not observed in the group that started late, as reported. The KEEPS study, conducted around a similar period, also explored what meaning early hormone use has.
That even with the same treatment, "when" can change the result. This is why, in hormone therapy, the individual's timing should be weighed through a consultation.
However, such study results are average tendencies and do not mean the same conclusion applies to everyone. Only by evaluating individual risk factors like thrombosis, breast, and liver function together is a judgment on safety possible. If you are curious about the start timing and duration, you can also refer to the how long should hormone therapy be continued item.
The way data helps personalized decisions
To gauge an individual's timing, you must look at a flow rather than a single scene. In the clinic, the direction of change over time often tells more than a single value. The data-based approaches drawing attention recently generally look at three axes together.
- Blood data: estradiol, FSH, lipids, liver function, and other basic indicators that gauge safety and the menopausal stage
- Symptom log: changes repeatedly recorded in daily life, like hot flashes, sleep quality, and mood change
- Wearable indicators: signals continuously collected, such as body-temperature trends, heart rate, and sleep patterns
Overlaying these three axes can reveal patterns that did not show well with a one-off test. For example, reading together the time sequence in which, as estrogen decline progresses, sleep is disrupted and hot flashes grow frequent. In clinical experience, the symptom flow a patient records themselves fills in context easily missed within the time of a visit.
Femtech and wearables, how far have they come
Women's health technology, so-called femtech, is growing rapidly recently. As of 2023, the market scale was assessed at a considerable level, and growth is reported to continue afterward. In the menopause area too, symptom-tracking apps and wearables are increasing.
In the wearable camp, attempts have emerged to show daily signals like sleep, body temperature, and heart rate alongside hormone data, and some devices and apps are developing into a form that links hormone-test data and lifestyle indicators on one screen. If you are interested in menopause self-recording and home testing, the article on how to check hormones at home covers it in more detail.
However, one thing is good to make clear. Most of these services are not medical practice but auxiliary tools that help recording and understanding. An app does not, on its own, decide the timing or dose of hormone therapy, and the final judgment must be made together through a visit. Through data, "understanding the changes of my body in numbers and sensing the direction of change in advance" — that far is the realistic use at the current stage.
If sleep changes or hot flashes bother you, just bringing your records organized makes the consultation proceed much more concretely. Inquire about a symptom-record consultation
Blood, symptoms, wearables, how to read them differently
The three kinds of data each have different strengths and limits. Rather than drawing a conclusion from any one alone, it is important to look at them together so they fill in each other's gaps. In particular, during the menopause transition, since the hormone values themselves fluctuate greatly, you must remember that it is hard to declare from a single blood test.
| Data type | What it mainly tells | Cautions in interpretation |
|---|---|---|
| Blood test (estradiol, FSH) | Gauging the menopausal stage, evaluating safety | In the transition, variation is large, so hard to declare from a single value |
| Symptom log | The frequency and intensity of changes in daily life | Subjective record, so a standard must be set and recorded steadily |
| Wearable indicators | The continuous trend of sleep, body temperature, heart rate | Affected by the measurement environment, a reference signal, not a medical diagnosis |
In fact, ACOG and NAMS recommend a symptom-centered approach over test values first in diagnosing the menopause transition. So in a visit, we discuss the timing by placing not a single line of values but the flow of symptoms, accompanying diseases, and the individual's priorities together. If you are troubled by hot flashes or sleep problems, you can examine it carefully starting from menopausal symptoms care.
Points to be sure to note when using data
The data-based approach is certainly useful, but it has meaning only when a few premises are kept. Let me organize the three I always emphasize to patients in the clinic.
- The place of an auxiliary tool: an algorithm or app is a tool that helps judgment, not a replacement for a doctor's care. Data interpretation has the possibility of error, so human cross-verification is needed.
- Safety evaluation first: not only hormone values but evaluation of individual risk factors like thrombosis, breast, and liver function comes first. This part is also why the expression "AI answers" is premature.
- Personal-information protection: hormone and reproductive health data are very sensitive. Only when the principles of consent, encryption, and purpose limitation are kept can it be used with peace of mind.
In the end, data is close to a common language that helps the doctor and patient talk while looking at the same picture. If you are worried about the safety of hormone therapy, please check the risks and safety of hormone therapy item together.
In closing: timing is decided together
That timing matters in hormone therapy, and that data helps in gauging that timing, is clear. But data does not decide on your behalf. Values and records are the starting point, and the process of adding the individual's medical history and priorities to them and deciding the timing together is the visit. When you feel a change, we recommend getting a consultation once before it is too late. At menopausal hormone care and hormone intensive care, you can get a consultation tailored to your individual situation.
If changes like sleep, hot flashes, and vaginal dryness overlap and you are at a loss about where to start, feel free to leave an inquiry. Get a consultation on hormone-therapy timing
Written by: Lee Dong-hee, Director · OB/GYN Specialist · View physician profile
First published October 24, 2025 · Last reviewed May 30, 2026
References: North American Menopause Society 2022 Hormone Therapy Position Statement (2022), ELITE Trial (2016), KEEPS Study (2019), ACOG Clinical Guidance on Menopause (2023)
This article is intended to provide general health information and is not a substitute for individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.